Accelerate Diagnostics

Accelerate Diagnostics Accounts Payable

Delisted

The Accounts Payable of Accelerate Diagnostics (AXDX) as of Nov 10, 2026 is 4.84 M USD. In the previous year, Accounts Payable was 4.80 M USD — a change of 1.00% (higher).

Accounts Payable

4.84 MUSD

YoY

1.00%

Last updated:

Accounts Payable of Accelerate Diagnostics is 2024 4.84 M USD. Accounts Payable of Accelerate Diagnostics was 2023 4.80 M USD. It decreases by 1.00% higher compared to the previous year.

The Accelerate Diagnostics Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2017
2.08 M USD
Jan 1, 2018
1.32 M USD
Jan 1, 2019
2.35 M USD
Jan 1, 2020
1.29 M USD
Jan 1, 2021
1.98 M USD
Jan 1, 2022
4.50 M USD
Jan 1, 2023
4.80 M USD
Jan 1, 2024
4.84 M USD
The Accelerate Diagnostics Accounts Payable history
YEARAccounts PayableYoY
4.84 MUSD+1.00%
4.80 MUSD+6.55%
4.50 MUSD+126.98%
1.98 MUSD+53.72%
1.29 MUSD-45.13%
2.35 MUSD+77.84%
1.32 MUSD-36.44%
2.08 MUSD+109.68%
992,000.00USD-62.18%
2.62 MUSD+23.20%
2.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Accounts Payable of Accelerate Diagnostics is 4.84 M USD in 2024.

Accounts Payable of Accelerate Diagnostics changed from 4.80 M USD to 4.84 M USD, representing a 1.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics